Dose-dense adjuvant chemotherapy in patients with HER2-low early breast cancer: An exploratory analysis of the GIM2 trial. Cost consequence model of the MammaPrint (70-gene signature) and 21-gene ...
Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology Three models for yearly time series predictions were built: autoregressive integrated ...
(Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Proteograph ® Product Suite, has been selected as the mass spectrometry-based proteomic ...
The probability of overall survival after 1, 5, and 10 years was predicted by a nomogram model, which found that worse Surveillance, Epidemiology, and End Results (SEER) stage was associated with ...